,
your personalized virtual assistant to find clinical trials. Go head, 
Michael Morse, MD
Duke Cancer Research Institute, Duke ...Durham, North Carolina - 27710 (919-971-0276) Duke University Medical CenterDurham, North Carolina - 27710 Duke Comprehensive Cancer CenterDurham, North Carolina - 27710 (919-668-1409) |
- CLINICAL TRIALS 7
- CONDITIONS17
- INTERVENTIONS9
- SINCE2007
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
June 2010 - June 2011
Phase I/II Trial of Radiation Avastin and Tarceva for Pancreatic Adenocarcinoma
July 2008 - December 2011
Immunotherapy Study for Surgically Resected Pancreatic Cancer
April 2010 - January 2014
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian Breast and Prostate Cancer
March 2010 - May 2011
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
July 2009 - July 2011
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
April 2008 - August 2011
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML CML ALL MDS and B Cell Malignancies
June 2007 - June 2010
Breast Neoplasms
Colonic Neoplasms
Lung Neoplasms
Adenocarcinoma
Prostatic Neoplasms
Leukemia
Leukemia, Lymphoid
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic Syndromes
Preleukemia
Ovarian Neoplasms
Pancreatic Neoplasms
Carcinoid Tumor
Ad5 Cea Vaccine
Lapatinib
Avastin And Tarceva
Hyperacute-Pancreas Immunotherapy
Dpx-0907 Consists Of 7 Tumor-Specific Hla-A2-Restricted Peptides, A Universal T Helper Peptide, A Polynucleotide Adjuvant, A Liposome And Montanide Isa51 Vg
Octreotide
Dher2 + As15 Asci
Pasireotide
Wt1 Derived Peptides
